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Abstract
Context: The novel coronavirus disease (COVID-19) is one of the most threatening pandemics in history involving multiple organs,
including the kidney. This study aimed to review the association of COVID-19 with renal involvement.
Evidence Acquisition: International databases, including the Web of Science, PubMed, Scopus, and Google Scholar, were searched
for articles by April 1, 2020. Keywords were COVID-19, coronavirus disease, SARS-CoV-2, kidney, renal function, acute kidney injury,
and acute renal failure, or a combination of them in title/abstracts.
Results: There were a few studies concerning COVID-19 and renal failure due to the short time elapsed from the epidemic onset. The
results showed that hematuria and proteinuria were common in patients with COVID-19.
Conclusions: Patients with elevated creatinine are at risk of mortality two times more than patients with normal creatinine. Also,
elevated BUN, proteinuria, and hematuria can increase the risk of mortality in patients with COVID-19 up to four times compared to
patients with normal tests. Therefore, it is important to check creatinine, BUN, proteinuria, and hematuria in primary assessments.
Generally, all routine measures for people affected with COVID-19 can be done for COVID-19 patients with acute renal failure until
the current knowledge is changed. Chloroquine phosphate may improve the chance of treatment.
Keywords: COVID-19, Renal Involvement, Kidney, Infection, Novel Coronavirus, Chloroquine
1. Coronavirus Disease
Coronaviruses are major pathogens that mainly tar-
get the human respiratory tract. The previous outbreaks
of coronaviruses, including Severe Acute Respiratory Syn-
drome (SARS) and Middle East Respiratory Syndrome
(MERS), showed to be highly threatening for public health.
In late December 2019, several patients were admitted to
hospitals whose initial diagnosis was pneumonia of un-
known etiology. These patients were linked to a seafood
wholesale market in Wuhan, Hubei province, China (1, 2).
Coronaviruses include a large family of viruses that are re-
sponsible for a subset of diseases varying from the com-
mon cold to more severe infections including SARS, MERS,
and Coronavirus Disease 2019 (COVID-19). The latest type
of them spreading to humans is COVID-19 (3). Initial re-
ports predicted the start of a potential coronavirus epi-
demic with estimates of the basic reproduction number
(R0) for the new (COVID-19, designated by the World Health
Organization on 11 February 2020), which was significantly
higher than one (ranging from 2.24 to 3.58) (4).
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) is the cause of COVID-19 (5). Nowadays, COVID-
19 is spread worldwide, resulting in the century pandemic
(6, 7). The main symptoms of COVID-19 are high tempera-
ture (fever), cough, and shortness of breath. The affected
patients develop pneumonia and multi-organ failure end-
ing to death. Almost all expired patients had severe comor-
bidities, such as cardiovascular disease and diabetes melli-
tus (8, 9). Wang et al. showed that the median time from
obvious symptoms to death was two weeks, but in some
cases, it lasted up to six weeks (10). Many factors can af-
fect the mortality rate. According to the current research
and knowledge, accessibility to medical services, and so-
cioeconomic status can play important roles in this regard
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(11). The sharp trend of this pandemic infection is life-
threatening for humans and must ring a bell for everyone,
especially at-risk patients.
At present, the novel coronavirus has a mortality rate
of about 2% to 3%, but it possibly changes as the virus con-
tinues to spread, while SARS virus mortality is about 14% to
15%. Most deaths of COVID-19 occur in elderly people with
other health problems such as heart disease, hypertension,
and diabetes. According to statistics, this group of people
is at greater risk of death than others due to diseases like
the flu (8).
2. COVID-19 Infection and Acute Renal Failure
To find the relationship between COVID-19 infection
and acute renal failure, in this review, international
databases, including the Web of Science, PubMed, Scopus,
and Goggle scholar, were searched for articles up to 17
March 2020. Keywords were COVID-19, coronavirus dis-
ease, SARS-CoV-2, kidney, renal function, acute kidney in-
jury, and acute renal failure, or a combination of them in ti-
tle/abstracts. For the sensitivity of the search, after examin-
ing the titles, irrelevant studies were removed, and the re-
maining studies were assessed by relevant specialists. The
syntax sample for PubMed was as follows: ((((COVID-19 [Ti-
tle/Abstract]) OR coronavirus [Title/Abstract]) OR SARS-CoV-
2 [Title/Abstract])) AND (((renal function [Title/Abstract])
OR renal [Title/Abstract]) OR acute kidney failure [Ti-
tle/Abstract]) OR acute renal failure [Title/Abstract])) AND
(("2019/01/12"[PDat]: "2020/03/17"[PDat])).
We know that renal and heart failures are life-
threatening events. According to the study by Dong et
al., on 2,143 pediatric patients with COVID-19 in China,
children with COVID-19 can quickly progress to Acute
Respiratory Distress Syndrome (ARDS), resulting in shock,
encephalopathy, heart failure, coagulopathy, and acute re-
nal failure injury (12). Given that COVID-19 makes patients
susceptible to dysfunction in multiple organs, including
the cardiovascular system, digestive tract, nervous system,
and kidneys, the question is that what is the treatment
method in the affected patients with renal failure (13)? For
responding to this question, it is essential to review the
treatment of patients in similar conditions, e.g., people
developing SARS or MERS. MERS and SARS are similar viral
diseases affecting many people, and compared to COVID-
19, they have high mortality rates of about 37% and 10%,
respectively. However, both of them are less contagious
than COVID-19. The COVID-19 disease is very contagious,
with a lower mortality rate than MERS and SARS (14, 15).
Another reason facilitating the spread of transmission
is the similarity of COVID-19 to influenza. Both diseases
have similar symptoms causing respiratory involvement
and sometimes death. Additionally, they both are trans-
mitted by contact and T-zone contamination by droplets
and fomites. Measures to prevent their development are
the same, including keeping hand hygiene and using res-
piratory masks (16, 17). Transmission is the fundamental is-
sue in epidemics, and the passengers are the main trans-
porters of the virus to other countries. More than 30% of
transmission cases happen by the nosocomial route, and
it is the main route of transmission for coronavirus infec-
tions in adults. The possibility of virus transmission from
children to other people has been approved. Since children
develop mild symptoms without the need for hospitaliza-
tion, the rate of contact, and infection transmission from
children to health care workers is low (18-22). One-third
of COVID-19 cases had exposure to the epidemic area, and
about 90% of children had close contact with their family
(23).
Figures 1 and 2 show the sharp increasing trend of
the epidemiologic curve by 1 April 2020. MERS, similar to
COVID-19, is often accompanied by Acute Respiratory Dis-
tress Syndrome (ARDS) and organ dysfunction (24). Re-
garding kidney injury following coronavirus infections,
MERS is responsible for severe renal involvement that dras-
tically affects the kidneys as it is not observed in any other
human coronavirus infection. However, the mechanism
of renal failure following MERS is not known exactly (25,
26). It is possible that restricting oxygen to vital organs can
cause dysfunction in the kidneys and the brain.
Unlike other coronaviruses that mostly affect the hu-
man respiratory tract, the virus can affect various organs,
including respiratory tissues, liver, kidneys, intestine, and
body’s immune cells. That is why patients usually have
multiple dysfunctions and finally pass away (5). Studies
showed acute renal failure during MERS and SARS, but SARS
is less likely to affect kidney epithelial cells. In contrast,
acute renal failure was observed in many patients with
MERS influencing the severity of disease (27, 28).
3. Diagnostic Methods
By the early diagnosis, the sharp trend gets wider in
such a way that the isolation of affected people can in-
terrupt the chain of transmission. The standard method
of COVID-19 diagnosis is real-time Reverse Transcription
Polymerase Chain Reaction (rRT-PCR). Another method in-
cludes nasopharyngeal swabs and blood sampling, but it
takes 14 days, and in this situation cannot be a suitable
method (6, 29, 30).
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Figure 2. Total recovered and affected cases of COVID-19 (source: World meter: www.worldometers.info)
4. Treatment of Acute Renal Failure Following COVID-
19 Infection
After diagnosis, the supportive treatment should start
as soon as possible. Regarding renal failure, COVID-19
patients whose disease is accompanied by renal failure
should receive supportive treatment as it is done for pa-
tients with renal failure without COVID-19. Also, kidney re-
placement therapy is another choice for them. By now, no
effective antiviral medication exists to treat these patients.
New medicines cannot be prescribed without approved re-
sults (31). All routine measures for people affected with
COVID-19 can also be done for COVID-19 patients with acute
renal failure until the current knowledge is changed be-
cause this disease is a new pandemic that will be more clear
in the future; the current knowledge may be changed by at-
taining new information in this regard (32). To the best of
our knowledge, COVID-19 tends to involve multiple organs,
and the kidney is one of them, as shown in two studies.
Acute kidney injury was reported in 5.1% of the patients. Pa-
tients with renal failure have a higher risk to be expired (33-
36). Various studies report multiple-organ failure. Regard-
ing the lungs, about half of the patients were involved with
moderate pneumonia, and 20% have acute upper respira-
tory symptoms. Chu et al. showed that 6.7% of the patients
developed acute renal impairment at a median duration of
20 days after the onset of disease (33, 37). Liver impairment
was reported in about 60% of the patients with the eleva-
tion of aspartate aminotransferase (38).
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5. Common Symptoms in COVID-19 Patients with Renal
Failure
Studies revealed the high rate of renal involvement in
patients with COVID-19. Two common symptoms in COVID-
19 patients with renal failure are hematuria and protein-
uria as albumin in the urine. Another major issue is im-
paired renal function in COVID-19 patients so that two-
thirds of expired patients experienced kidney dysfunction,
and about one-fourth of discharged COVID-19 patients had
impaired renal function. These symptoms are life- threat-
ening, especially in patients with other comorbidities.
Only 15% of the kidney function remained in COVID-19 pa-
tients. This can be a crucial symptom for the diagnosis of
COVID-19 in patients with flu-like symptoms. It means that
patients with renal failure should be checked regarding
COVID-19 in the present and future. The authors think that
a differential diagnosis (DDX) of acute renal failure should
be COVID-19.
Understanding the fact that multi-organ dysfunction
following COVID-19 is the main cause of death in patients
necessitates it for clinicians to be alert because multiple-
organ failure such as acute respiratory distress syndrome,
heart failure, and renal failure in the present infection is
sophisticated to be treated (39). Particularly, infants, peo-
ple more than 60 years, pregnant women, and in-patients
with severe comorbidities are vulnerable to COVID-19 and
should stay at the intensive care unit. We know that COVID-
19 involves the kidneys and results in acute renal failure,
but in patients with chronic kidney disease, the effect of
the virus is vague and unknown (40).
6. Do ACE Inhibitors Influence COVID-19 Disease?
On 15 March 2020, the Renal Association of the UK
asserted that Angiotensin-converting Enzyme (ACE) in-
hibitors and angiotensin receptor blockers could not in-
crease the chance of mortality by COVID-19 disease in such
a way that provoking anxiety in patients with kidney dis-
ease is threatening. After stopping the ACE inhibitors,
heart failure may arise. Breathlessness can be intensified
by stopping the drugs of interest so that it makes it hard for
clinicians to distinguish whether the symptoms are due to
underlying health problems or COVID-19 disease. Stopping
the drugs depends on the clinical condition except for hav-
ing COVID-19 infection. Therefore, taking ACE inhibitors is
not precluded (41, 42). The authors think that another dif-
ferential diagnosis (DDX) of flu-like symptoms should be
the use of ACE inhibitors. Now, there are no exact statistics
about the number of COVID-19 patients developing acute
renal failure; for example, we do not know what percent-
age of 7,426 COVID-19 patients by March 17 died due to acute
renal failure (27). The importance of this event will be clear
after new cohort studies and further cross-sectional assess-
ments.
7. Chloroquine for COVID-19 Infection
So far, there is no approved drug for treating COVID-
19 patients not only for antiviral effects but also for other
symptoms including acute renal failure. Considering that
acute renal failure arises after COVID-19 development, it
seems that the treatment of COVID-19 disease is useful on
the path of renal impairment treatment. Starting antiviral
medications is proposed to maintain vital organs function;
hence, it can reduce the morbidity and mortality among
critical patients (43, 44). Chloroquine is a quinine of amine
acidotropic form, first synthesized in Germany in approxi-
mately 85 years ago (45). Chloroquine inhibits the comple-
tion of the viral cycle with the binding of viral particles to
cellular cell receptors (46, 47). Chloroquine phosphate has
been widely used as a medication to treat malaria for sev-
eral years. It has apparent efficacy with enough safety in
patients with COVID-19, as multicenter trials approved its
effect in China. Also, chloroquine may be included in the
next version of guidelines to treat COVID-19 issued by the
National Health Commission in China (48).
The benefits of chloroquine can be summarized as
follows: “chloroquine prevents SARS Cov-2 replication”,
“chloroquine slows down the activity of lots of viruses in
vitro”, "acute viral diseases in humans have been treated us-
ing chloroquine for several years", and "big data in China
show the effective role of chloroquine in the treatment of
COVID-19" (49). Also, chloroquine is used to treat chronic
viral diseases such as HIV infection (50). Additionally,
hydroxychloroquine is used in systematic immunodefi-
ciency diseases like rheumatoid arthritis and systemic lu-
pus erythematosus (51). Besides the wide use of chloro-
quine in different viral infections, the treatment of pa-
tients with COVID-19 infected by SARS-CoV-2 was observed
(49). The multicenter collaboration group of China re-
ported that chloroquine phosphate (chloroquine) had ac-
ceptable antiviral effects, including against coronaviruses,
increased the chance of treatment, reduced stay at the hos-
pital, and led to discharge with good condition in COVID-19
patients. The group recommended using 500 mg chloro-
quine phosphate tablets twice per day up to 10 days (52, 53).
8. Positive RT-PCR Test After Recovery From COVID-19 In-
fection
On 17 February 2020, four discharged patients were re-
ported to be a new challenge in the treatment of patients
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with COVID-19 infection. Thus, follow-ups should be con-
sidered regularly by telephone or email in these patients.
Patients’ e-mails are intended to reduce both in-person vis-
its and the risk of recurrence because the best way to pre-
vent COVID-19 infection is to keep far from exposure to
the virus (30, 54). Although there were only four patients,
which are not enough to make a clinical decision, it can
make us aware of the importance of following up.
9. Conclusions
It is important to check creatinine, blood urea nitro-
gen (BUN), proteinuria, and hematuria on admission be-
cause patients with elevated creatinine are at risk of mor-
tality two times more than patients with normal creati-
nine. Also, elevated BUN of about four times, proteinuria
up to four times, and hematuria up to five times can in-
crease the risk of mortality in patients with COVID-19. Con-
sidering that about 5% of patients referring to hospitals
develop renal failure, it is important to check creatinine,
BUN, proteinuria, and hematuria in the primary assess-
ment. Taking the ACE inhibitors can be useful and its stop-
page is not recommended. Chloroquine phosphate may
improve the chance of treatment. Due to the probability
of COVID-19 recurrence after recovery, the follow-up should
be considered regularly by telephone or email in these pa-
tients. Generally, all routine measures for people affected
by COVID-19 can be done for COVID-19 patients with acute
renal failure until the current knowledge is changed. It is
proposed to perform longitudinal studies to assess the re-
nal function and development of kidney disease to provide
strong documents in favor of decision-making.
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